COMMUNIQUÉS West-GlobeNewswire

Soda Health Rebrands As Evermore, An Outcomes Company, Reflecting Its Mandate As The Leader In Smart Benefits Administration
07/10/2025
The move reflects the broader role the company is playing coordinating benefit funds across programs to reduce fraud and waste, tying dollars to outcomes BENTONVILLE, Ark., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Soda Health [...]
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
07/10/2025
DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
07/10/2025
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less [...]
Jade Biosciences Announces $135 Million Private Placement
07/10/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
07/10/2025
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve [...]
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
07/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
07/10/2025
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
07/10/2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
07/10/2025
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and [...]
Parexel Expands Global Site Alliance Program, Delivering 40% Faster Site Activation, 20% Faster Study Start Up Timelines and Four Times More Patient Enrollments Per Site
07/10/2025
Parexel’s Site Alliance Program strengthens global partnerships with clinical research sites and reinforces leadership in site engagement excellence RALEIGH, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading [...]
Privia Health to Report Third Quarter 2025 Results on Thursday, November 6
07/10/2025
ARLINGTON, Va., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, [...]
Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®
07/10/2025
Nausea and Vomiting Are the Most Frequent Reasons for Discontinuing GLP-1 Therapies, Significantly Impacting Adherence, Titration and Preventing Achievement of Proven Long-Term Benefits WOBURN, Mass., Oct. 07, 2025 ( [...]
MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets
07/10/2025
MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc [...]
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
07/10/2025
MELBOURNE, Australia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing treatments for recurring and metastatic [...]
GATC Health Announces Launch of Derisq: The Definitive AI Report for Predictive Risk Assessment of Drug Candidates at Fierce Biotech Week 2025
07/10/2025
Derisq delivers actionable insights about drug safety, efficacy and off-target risks prior to committing development capital BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GATC Health, a leading tech-bio company leveraging [...]
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
07/10/2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc [...]
Prenetics Completes $72 Million ACT Exit, Bolsters Cash and Bitcoin Treasury to Accelerate IM8’s Path to $100 Million ARR
07/10/2025
Strengthens Balance Sheet with Over $60 Million in Cash 1 , Excluding Bitcoin Treasury David Beckham Co-Founded IM8 on Track to Achieve $100 Million ARR in First Year, Becoming One of the Fastest-Growing Supplement [...]
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
07/10/2025
FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for [...]

Pages